ATE539159T1 - Genetische varianten von menschlicher inositolpolyphosphat-4-phosphatase typ i (inpp4a) mit eignung zur vorhersage und therapie immunologischer erkrankungen - Google Patents

Genetische varianten von menschlicher inositolpolyphosphat-4-phosphatase typ i (inpp4a) mit eignung zur vorhersage und therapie immunologischer erkrankungen

Info

Publication number
ATE539159T1
ATE539159T1 AT06809100T AT06809100T ATE539159T1 AT E539159 T1 ATE539159 T1 AT E539159T1 AT 06809100 T AT06809100 T AT 06809100T AT 06809100 T AT06809100 T AT 06809100T AT E539159 T1 ATE539159 T1 AT E539159T1
Authority
AT
Austria
Prior art keywords
inpp4a
disorders
inositol polyphosphate
asthma
prediction
Prior art date
Application number
AT06809100T
Other languages
English (en)
Inventor
Balaram Ghosh
Mamta Sharma
Jyotsna Batra
Original Assignee
Council Scient Ind Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Scient Ind Res filed Critical Council Scient Ind Res
Application granted granted Critical
Publication of ATE539159T1 publication Critical patent/ATE539159T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT06809100T 2005-10-25 2006-10-23 Genetische varianten von menschlicher inositolpolyphosphat-4-phosphatase typ i (inpp4a) mit eignung zur vorhersage und therapie immunologischer erkrankungen ATE539159T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1536DE2005 2005-10-25
PCT/IB2006/002963 WO2007049118A1 (en) 2005-10-25 2006-10-23 Genetic variants of human inositol polyphosphate-4-phosphatase, type i (inpp4a) useful for prediction and therapy of immunological disorders

Publications (1)

Publication Number Publication Date
ATE539159T1 true ATE539159T1 (de) 2012-01-15

Family

ID=37741351

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06809100T ATE539159T1 (de) 2005-10-25 2006-10-23 Genetische varianten von menschlicher inositolpolyphosphat-4-phosphatase typ i (inpp4a) mit eignung zur vorhersage und therapie immunologischer erkrankungen

Country Status (8)

Country Link
US (1) US20070243539A1 (de)
EP (1) EP1954810B1 (de)
AT (1) ATE539159T1 (de)
AU (1) AU2006307640B2 (de)
CA (1) CA2627289A1 (de)
ES (1) ES2378395T3 (de)
NZ (1) NZ567726A (de)
WO (1) WO2007049118A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102010008827B3 (de) * 2010-02-22 2011-06-16 Universität Rostock Verfahren zur Diagnose oder Prädiagnose von Multipler Sklerose anhand von Einzelnukleotid-Polymorphismen des humanen Chromosoms 4 im Inositol-polyphosphat-4-phosphatase-Typ II-Gen (INPP4b-Gen)
US10468122B2 (en) * 2012-06-21 2019-11-05 International Business Machines Corporation Exact haplotype reconstruction of F2 populations
CN102808030B (zh) * 2012-08-21 2014-02-19 首都医科大学附属北京儿童医院 单核苷多态性rs3888188在检测结核病易感性中的应用
CN111778329B (zh) * 2020-09-01 2022-07-22 陕西九州医学检验有限公司 与哮喘相关基因的分子标记及其检测引物组和应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5541308A (en) * 1986-11-24 1996-07-30 Gen-Probe Incorporated Nucleic acid probes for detection and/or quantitation of non-viral organisms
US7625699B2 (en) * 2003-03-10 2009-12-01 Celera Corporation Genetic polymorphisms associated with coronary stenosis, methods of detection and uses thereof

Also Published As

Publication number Publication date
AU2006307640B2 (en) 2012-03-01
AU2006307640A1 (en) 2007-05-03
EP1954810B1 (de) 2011-12-28
CA2627289A1 (en) 2007-05-03
AU2006307640A2 (en) 2008-07-03
NZ567726A (en) 2012-03-30
US20070243539A1 (en) 2007-10-18
EP1954810A1 (de) 2008-08-13
ES2378395T3 (es) 2012-04-12
WO2007049118A1 (en) 2007-05-03

Similar Documents

Publication Publication Date Title
Xu et al. The roles of IL-1 family cytokines in the pathogenesis of systemic sclerosis
Dahlgren et al. Adventitial stromal cells define group 2 innate lymphoid cell tissue niches
Faas et al. IL-33-induced metabolic reprogramming controls the differentiation of alternatively activated macrophages and the resolution of inflammation
Drake et al. IL‐33: biological properties, functions, and roles in airway disease
Wirnsberger et al. IL‐4 induces expression of TARC/CCL17 via two STAT6 binding sites
Kragstrup et al. The IL-20 cytokine family in rheumatoid arthritis and spondyloarthritis
Walford et al. STAT6 and lung inflammation
Genovese et al. Biglycan fragmentation in pathologies associated with extracellular matrix remodeling by matrix metalloproteinases
Lin et al. Resistin family proteins in pulmonary diseases
Kobayashi et al. Critical role of CCL4 in eosinophil recruitment into the airway
Sun et al. Single cell RNA sequencing (scRNA-Seq) deciphering pathological alterations in streptozotocin-induced diabetic retinas
ATE539159T1 (de) Genetische varianten von menschlicher inositolpolyphosphat-4-phosphatase typ i (inpp4a) mit eignung zur vorhersage und therapie immunologischer erkrankungen
Lodovicho et al. Investigating possible biological targets of Bj-CRP, the first cysteine-rich secretory protein (CRISP) isolated from Bothrops jararaca snake venom
Fu et al. Highly selective cleavage of TH2-promoting cytokines by the human and the mouse mast cell tryptases, indicating a potent negative feedback loop on TH2 immunity
Getz et al. Human pharmacokinetics/pharmacodynamics of an interleukin‐4 and interleukin‐13 dual antagonist in asthma
Pandey et al. Gaucher disease: chemotactic factors and immunological cell invasion in a mouse model
Qin et al. The role of IL-36γ and its regulation in eosinophilic inflammation in allergic rhinitis
Aydt et al. Development of synthetic pan-selectin antagonists: a new treatment strategy for chronic inflammation in asthma
Douglas et al. Interleukin-17 as a key player in neuroimmunometabolism
McGee et al. Differential effects of particulate matter upwind and downwind of an urban freeway in an allergic mouse model
Esnault et al. Increased IL‐6 and Potential IL‐6 trans‐signalling in the airways after an allergen challenge
Castan et al. Food allergen‐sensitized CCR 9+ lymphocytes enhance airways allergic inflammation in mice
Izbicki et al. Bleomycin-induced lung fibrosis in IL-4-overexpressing and knockout mice
Helou et al. Human PD-1 agonist treatment alleviates neutrophilic asthma by reprogramming T cells
Izuhara The role of interleukin-4 and interleukin-13 in the non-immunologic aspects of asthma pathogenesis